 |
 |
In a message dated 11/3/2001 8:27:32 AM Eastern Standard Time, [log in to unmask] writes: I received the following message from CenterWatch about clinical trials in many locations for rasagiline. SEE summary of the study below and the forwarded message. Is anyone already participating in a trial of this drug? Linda Linda, I have been participating in the rasagiline trial at the Duke University site since Sept. The drug is an advanced form of Eldepryl. It is a small pill that is taken only once a day. They are also looking for neuroprotective properties (i.e. slowing or halting of the degeneration of the brain). The trial is in Phase III. In the first two phases, minimal side effects were found. For the first six months of the trial, one-half of the subjects take the drug and the other half takes a placebo. In the second six months, all subjects take the drug. Subjects are required to do some "homework" occasionally. For a few sets of three days each, each subject must record his/her ON/OFF periods. There are also times when you have to keep a diary of what you eat for your main meal each day and record your blood pressure before and after the meal (this is very simple -- you receive a device has the usual cuff that squeezes your arm, but it is activated by the push of a button, provides a digital read-out of the pressure and pulse rate, and sends the data via internal modem to the clinical trial site). I also sent out the CenterWatch notice just before I read your posting. Sorry for the duplication, folks. Let me know if you have any questions. Rees Jenkins ---------------------------------------------------------------------- To sign-off Parkinsn send a message to: mailto:[log in to unmask] In the body of the message put: signoff parkinsn